Charles River Laboratories
$ 167.74
-9.23%
23 Apr - close price
- Market Cap 9,118,394,000 USD
- Current Price $ 167.74
- High / Low $ 180.85 / 165.55
- Stock P/E N/A
- Book Value 64.30
- EPS -2.90
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.04 %
- ROE -0.04 %
- 52 Week High 228.88
- 52 Week Low 112.12
About
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
Analyst Target Price
$199.33
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-18 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-19 | 2024-11-06 | 2024-08-07 | 2024-05-09 | 2024-02-14 | 2023-11-08 | 2023-08-09 | 2023-05-11 |
| Reported EPS | 2.39 | 2.43 | 3.12 | 2.34 | 2.66 | 2.59 | 2.8 | 2.27 | 2.46 | 2.72 | 2.69 | 2.78 |
| Estimated EPS | 2.35 | 2.35 | 2.55 | 2.07 | 2.53 | 2.42 | 2.39 | 2.07 | 2.4 | 2.37 | 2.64 | 2.59 |
| Surprise | 0.04 | 0.08 | 0.57 | 0.27 | 0.13 | 0.17 | 0.41 | 0.2 | 0.06 | 0.35 | 0.05 | 0.19 |
| Surprise Percentage | 1.7021% | 3.4043% | 22.3529% | 13.0435% | 5.1383% | 7.0248% | 17.1548% | 9.6618% | 2.5% | 14.7679% | 1.8939% | 7.3359% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.96 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRL
2026-04-24 05:37:52
IQVIA Holdings Inc. (IQV) stock fell on Thursday, underperforming its competitors. The stock closed down $2.77 to $257.26, while the S&P 500 also saw an increase.
2026-04-23 18:38:51
CRA International Inc.'s stock recently hit a 52-week low of $149.96, reflecting significant declines over the past year. Despite this downturn, InvestingPro analysis suggests the stock may be undervalued given its P/E ratio relative to near-term earnings growth potential. The company also announced strong Q4 and full-year 2025 financial results and a leadership change.
2026-04-23 17:25:20
Charles River Laboratories International (NYSE:CRL) saw its stock plunge by 7.2% to $171.57 due to a broad sector-wide selloff in the diagnostics and research industry. This decline was not attributed to company-specific issues but rather a synchronized downturn affecting multiple peers, with MEDP dropping 23.0% and RVTY falling 9.4%. The selling pattern suggests investors are re-positioning away from the sector, impacting CRL's valuation despite its essential drug development services.
2026-04-23 16:37:18
Charles River Laboratories International (NYSE:CRL) experienced a 7.2% decline in its stock price, closing at $171.57, as a result of a widespread selloff affecting the diagnostics and research sector. The downturn, which saw several peer companies also fall dramatically, suggests a sector-wide repositioning by investors rather than company-specific issues for Charles River. The company's market capitalization reduced to $8.5 billion, highlighting its sensitivity to broader healthcare research spending sentiment amid the synchronized market movement.
2026-04-23 16:30:00
Shares of Charles River Laboratories International Inc. (CRL) fell by 9.23% to $167.74 on Thursday, underperforming against a broader market decline. The S&P 500 Index (SPX) dropped 0.41% and the Dow Jones Industrial Average (DJIA) fell 0.36%. CRL's stock closed 26.71% below its 52-week high of $228.88.
2026-04-23 15:38:51
First Merchants Corporation reported first-quarter adjusted earnings of $1.03 per share, significantly beating the Wall Street consensus of $0.95. The company generated $248.6 million in revenue, an 11.7% increase from the prior year, and achieved a net income of $27.8 million. Analyst sentiment remains positive, with a strong consensus of buy ratings for the stock.
